4 Engineers, including BME's J. Paul Robinson, advancing their technologies through Trask funding
Four engineers among six Purdue researchers who received a total of $208,628 from the Trask Innovation Fund to help their labs commercialize their innovations.
The fund is a development program established to support projects that advance the commercial value of Purdue intellectual property. The fund makes awards twice a year to aid faculty and staff with their patented innovations that are being commercialized through the Purdue Research Foundation Office of Technology Commercialization .
There are three Trask Innovation Fund tracks: Innovation Sparks for Life Science (life science), Innovation Sparks for Physical Sciences (physical science) and Commercialization Partner Spark (commercialization).
The Purdue engineers receiving funding this round are:
- Na (Luna) Lu, ACPA Professor of Civil Engineering and Materials Engineering by courtesy, for prototyping piezoelectric sensing device for real-time concrete strength monitoring (track: commercialization) ~ read more
- Pedro Irazoqui, Reilly Professor of Biomedical Engineering and Professor of Electrical and Computer Engineering, for a wearable alerting device for monitoring impending SUDEP risk through multiple biomarkers (track: commercialization) ~ read more
- J. Paul Robinson, The SVM Professor of Cytomics and Professor, Weldon School of Biomedical Engineering, for a handheld device for real-time detection of pathogens, toxins and contaminating chemicals for biodefense and food analysis (track: physical sciences) ~ read more
- Jeffrey Youngblood, Professor of Materials Engineering, for processing of near-minimum viable product prototype for biodegradable packaging from cellulose nanofibrils (track: physical sciences) ~ read more
Additional Purdue researchers receiving funding are:
- Jean Chmielewski, cell penetrating antibacterial peptides for treatment of serious lung infections (track: life science)
- Arun Bhunia, authentication of listeria adhesion protein (LAP)-mediated drug delivery across the epithelial barrier (track: life science)
“Even during a global pandemic, researchers created many technologies worthy of OTC’s investment to develop solutions through the Purdue commercialization ecosystem and Purdue’s growing Discovery Park District,” said Abhijit Karve, director of business development for OTC.
Purdue inventors who are prepared to move their innovations to market have until Feb. 19 to apply for funding through the Trask Innovation Fund.
All Purdue faculty, staff and researchers who have submitted a disclosure to OTC are eligible to submit proposals.
To learn more about these and other Purdue technologies, contact OTC at email@example.com or visit the OTC Inventions page at https://inventions.prf.org/.
Source: Purdue Research Foundation News